Carlo Conti is a partner in the field of life sciences and health law. He advises institutions and organizations on questions of life sciences and health law and on matters of governmental and administrative law. He is a member of a number of boards of directors. He is also a lecturer on health law at the University of Basel law school and regularly speaks at national and international conferences.
He has many years of professional experience and deep knowledge of all areas of life sciences and health law, as well as governmental and administrative law. He held executive positions in the pharmaceutical industry for more than 15 years. Carlo Conti then served as member of the State Council for Basel-Stadt Canton where he was head of the public health department. He was also president of the Swiss Conference of Public Health Ministers and chairman of the board of Swiss DRG AG and vice-chairman of the agency council of Swissmedic.
Lecturer in health law at the University of Basel
Chairman of Basel Tourismus
Numerous mandates as President or Member of the Board of Directors of various companies
Board Member of various organisations
|2016||Partner Wenger Plattner|
|2014||Counsel Wenger Plattner|
|2000||Member and Vice-President of the Cantonal Government Basel-Stadt, Head of the Department of Public Health|
|1985||F. Hoffmann-La Roche AG, in senior management position Legal Department and Public Relations|
|1985||University of Basel (Dr. iur.)|
|1982||Attorney at Law|
|1978||University of Basel (lic. iur.)|
GLI - Pricing & Reimbursement 2019
Every resident in Switzerland is mandatorily obliged to be covered by basic healthcare insurance which provides for a wide range of services. Persons with lower incomes are, in principle, granted reductions on the premiums payable for such basic healthcare insurance. Thus, every resident in Switzerland is granted access to affordable healthcare. In general, therapeutic products are only reimbursed if they are listed on the so-called specialty list. In order to be listed thereon, a medicinal product must be admitted by the competent Swiss authority, and has to satisfy the criteria of effectiveness, functionality and economic efficiency, based on which the maximum price for the therapeutic product in question is determined.
GLI – Pricing & Reimbursement 2018
Every resident in Switzerland is mandatorily obliged to be covered by basic healthcare insurance which provides for a wide range of services. Persons with lower incomes are in principle granted reductions on the premiums payable for such basic healthcare insurance. Thus, every resident in Switzerland is granted access to affordable healthcare.
Versorgungsmanagement im Spannungsfeld zwischen Daten-, Patientenschutz und sektoralen Versorgungsgrenzen (in German)
In: Versorgungsmanagement in Gesundheitssystemen, Rebscher Herbert / Kaufmann Stefan (Hrsg.), Heidelberg 2013, S. 139 ff.